Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cue BiopharmaCUE +1.16%46 3-1 Month Momentum % is -6.55% as of Aug. 07, 2026. GuruFocus rates CUE with a GF Score™ of 46/100. The stock has 3 warning signs investors should review. Among 1,387 Biotechnology companies, Cue Biopharma ranks better than 55.01% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-07), Cue Biopharma's 3-1 Month Momentum % is -6.55%.
The industry rank for Cue Biopharma's 3-1 Month Momentum % or its related term are showing as below:
CUE's 3-1 Month Momentum % is ranked better than 55.01% of 1387
companies
in the Biotechnology industry
Industry Median: -6.98
vs CUE: -6.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cue Biopharma 3-1 Month Momentum % Related Terms
CUE vs CNTB, CDXS, HURA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Cue Biopharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a 3-1 Month Momentum % of -6.55% as of Aug. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #624 out of 1387 companies in the Biotechnology industry, placing it in the top 45%.
Is Cue Biopharma's 3-1 Month Momentum % too high?
Cue Biopharma's current 3-1 Month Momentum % is -6.55%. Based on the distribution chart, Cue Biopharma ranks #624 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's 3-1 Month Momentum % compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #624 out of 1387 companies for 3-1 Month Momentum %. This puts Cue Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current 3-1 Month Momentum % is -6.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Cue Biopharma (CUE) has a current 3-1 Month Momentum % of -6.55%. The current 3-1 Month Momentum % is -6.55%. Cue Biopharma's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cue Biopharma (CUE), the current 3-1 Month Momentum % is -6.55% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
46GF Score
Get the complete analysis for CUE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
